HAYWARD, Calif., Jan. 12, 2022 /PRNewswire/ — AcelRx Prescribed drugs, Inc. (NASDAQ: ACRX), a specialty pharmaceutical firm concentrated on the development and commercialization of modern therapies for use in medically supervised options, right now declared the publication of an editorial concerning the use of sufentanil sublingual tablet (SST DSUVIA®) in total joint replacement surgical procedures by Dr. Scott Sigman in the Journal of Orthopaedic Working experience and Innovation. Dr. Sigman is a board-accredited orthopedic surgeon at Orthopedic Surgical Associates of Lowell, the former Main of Orthopedics at Lowell Standard Healthcare facility in Lowell Massachusetts, and an internationally acknowledged leader in opioid-sparing orthopedic surgical procedures.
Dr. Sigman’s editorial, entitled “Opioid Stewardship: Is There a “Better” Opioid?,” reflects his qualified view on the not long ago printed short article in the similar journal entitled “Lessened opioid use and medical center continue to be in patients undergoing whole knee or whole hip arthroplasty when addressed with sublingual sufentanil in contrast with typical analgesic treatment” which was co-authored by Dr. Lawrence Wiesner and Dr. Christian Tvetenstrand from the United Health Products and services Orthopedic Heart in Vestal, New York and Southern Tier Surgical Clinic in Johnson Metropolis, New York. The review prospectively evaluated individuals who were administered a single SST 30 mcg in the perioperative interval and when compared their size of stay and total opioid use to matched historical management clients getting common IV opioids.
In the editorial, Dr. Sigman emphasizes the relevance of minimizing opioid publicity to the affected person as portion of very good Opioid Stewardship methods, and that doctors working with Enhanced Restoration Just after Surgery (ERAS) protocols should look at irrespective of whether there is an opportunity to further more cut down perioperative opioid exposure by the variety of the opioid analgesic they utilize. Dr. Sigman highlights the results from the Dr. Wiesner review, which demonstrated an around 30% reduction in the two all round opioid use and medical center length of remain in the SST-addressed individuals in contrast to the IV opioid group, as nicely as a reduction in the SST team of the quantity of people requiring discharge to a qualified nursing facility as a substitute of currently being discharged to dwelling.
As highlighted in the editorial, Dr. Sigman thinks the outcomes of this review discover SST as a feasible choice for the development of the beliefs of Opioid Stewardship with the likely to reduce opioid utilization, which could possibly decrease opioid-related adverse functions, length of continue to be, and probably lower the danger of bodily dependence and habit in the postoperative period of time. Whilst the examine was not double-blinded or placebo-controlled and the control group was a historical cohort, Dr. Sigman states, “The simple fact that the affected individual variety was not stringent, and that multiple styles of surgeries and anesthetic methods had been included, may perhaps in point allow a superior feeling of the utility of SST in a actual-globe clinical location as opposed to a remarkably controlled trial.”
“We be expecting Dr Sigman’s commentary on the importance of SST in minimizing the publicity of individuals to opioids in the perioperative setting to resonate with his surgical colleagues provided his global profile as an opioid-sparing surgeon” said Dr. Pamela Palmer, AcelRx Main Professional medical Officer and co-founder. “His advocacy of SST as a feasible option to advance the beliefs of Opioid Stewardship is a noteworthy declaration of the possible relevance of SST in the perioperative placing,” continued Dr. Palmer.
Dr. Sigman is a paid out advisor for AcelRx but was not compensated for this editorial. Dr. Wiesner is not a paid consultant for AcelRx. Dr. Tvetenstrand is a compensated specialist for AcelRx but was not compensated for the examine that is the subject matter of the editorial. AcelRx did not give funding for the carry out of the review that is the subject of the editorial but did fund healthcare writing assist.
About DSUVIA (sufentanil sublingual tablet), 30 mcg
DSUVIA®, known as DZUVEO® in Europe, is indicated for use in grown ups in licensed medically supervised health care options, this kind of as hospitals, surgical facilities, and crisis departments, for the administration of acute suffering significant enough to have to have an opioid analgesic, and for which substitute remedies are inadequate. DSUVIA was made to offer quick analgesia by using a non-invasive route and to get rid of dosing faults linked with intravenous (IV) administration. DSUVIA is a solitary-toughness reliable dosage type administered sublingually via a single-dose applicator (SDA) by health care gurus. Sufentanil is an opioid analgesic beforehand only marketed for IV and epidural anesthesia and analgesia. The sufentanil pharmacokinetic profile when delivered sublingually avoids the large peak plasma concentrations and limited duration of action noticed with IV administration. The European Commission permitted DZUVEO for marketing and advertising in Europe and it will be commercialized by AcelRx’s European companion, Aguettant.
This release is intended for traders only. For much more details, which includes essential basic safety data and black box warning for DSUVIA, you should pay a visit to www.DSUVIA.com.
About AcelRx Prescription drugs, Inc.
AcelRx Prescription drugs, Inc. is a specialty pharmaceutical firm centered on the advancement and commercialization of modern therapies for use in medically supervised configurations. AcelRx’s proprietary, non-invasive sublingual formulation know-how provides sufentanil with consistent pharmacokinetic profiles. The Enterprise has a single accepted merchandise in the U.S., DSUVIA® (sufentanil sublingual tablet, 30 mcg), identified as DZUVEO® in Europe, indicated for the management of acute pain significant enough to need an opioid analgesic for adult individuals in accredited medically supervised health care settings, and several solution candidates. The products candidates contain Zalviso® (sufentanil sublingual tablet method, SST system, 15 mcg), an investigational product in the U.S. being created as an innovatively made affected individual-managed analgesia (PCA) program for reduction of average-to-intense acute ache in medically supervised settings, and two pre-stuffed, completely ready-to-use syringes of ephedrine and phenylephrine licensed for the U.S. from Aguettant. DZUVEO and Zalviso are equally approved items in Europe.
For extra information about AcelRx, be sure to pay a visit to www.acelrx.com.
Look at first material to obtain multimedia:https://www.prnewswire.com/news-releases/acelrx-prescribed drugs-announces-publication-of-an-editorial-by-an-internationally-identified-leader-in-opioid-sparing-medical procedures-highlighting-the-likely-rewards-of-the-sufentanil-sublingual-pill-in-joint-substitute-surgical procedures-301459074.html
Resource AcelRx Prescribed drugs, Inc.